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Abstract: Current antifungal interventions have often limited efficiency in treating fungal pathogens,
particularly those resistant to commercial drugs or fungicides. Antifungal drug repurposing is an
alternative intervention strategy, whereby new utility of various marketed, non-antifungal drugs
could be repositioned as novel antifungal agents. In this study, we investigated “chemosensitization”
as a method to improve the efficiency of antifungal drug repurposing, wherein combined application
of a second compound (viz., chemosensitizer) with a conventional, non-antifungal drug could
greatly enhance the antifungal activity of the co-applied drug. Redox-active natural compounds or
structural derivatives, such as thymol (2-isopropyl-5-methylphenol), 4-isopropyl-3-methylphenol,
or 3,5-dimethoxybenzaldehyde, could serve as potent chemosensitizers to enhance antifungal activity
of the repurposed drug bithionol. Of note, inclusion of fungal mutants, such as antioxidant mutants,
could also facilitate drug repurposing efficiency, which is reflected in the enhancement of antifungal
efficacy of bithionol. Bithionol overcame antifungal (viz., fludioxonil) tolerance of the antioxidant
mutants of the human/animal pathogen Aspergillus fumigatus. Altogether, our strategy can lead to
the development of a high efficiency drug repurposing design, which enhances the susceptibility
of pathogens to drugs, reduces time and costs for new antifungal development, and abates drug or
fungicide resistance.
Keywords: antifungal intervention; antioxidant system; Aspergillus; chemosensitization; drug repurposing;
drug resistance; mutants; pathogen control
1. Introduction
There have been continuous efforts to develop new antifungal agents or to improve the efficacy of
conventional antifungal methods [1,2]. However, current intervention strategies often have limited
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efficiency in treating fungi, especially those pathogens resistant to drugs or fungicides [3]. The use of
high-throughput screenings/bioassays to develop new antifungal agents and/or define cellular targets
of newly-identified antifungal agents is still a developing field. This is especially true with regard
to determining the involvement of specific genes, genetic pathways or previously undetected lipid
changes in cellular membranes, cross talks between lipid molecules and mitochondrial dysfunction,
cell wall integrity and filamentous fungal growth, etc., which can explain resistance to conventional
antifungal agents [4–7].
Recently, increased incidences of fungal resistance to a class of azoles make fungal infections a
global human health issue [8]. Aspergillosis is an example. Aspergillosis is a fungal disease caused by
filamentous fungal pathogens in the genus Aspergillus [9]. Immuno-compromised groups of people or
patients with lung diseases are especially at risk of developing aspergillosis. Among the several types
of aspergillosis documented (such as allergic bronchopulmonary aspergillosis, allergic Aspergillus
sinusitis, aspergilloma, chronic pulmonary aspergillosis, invasive aspergillosis (IA), and cutaneous
aspergillosis) [10], IA is a particularly devastating infection triggered by environmental Aspergillus
species, wherein Aspergillus fumigatus is the leading agent of IA followed by A. flavus, A. terreus, A. niger,
and A. nidulans [9,10].
Certain azole fungicides, such as propiconazole or tebuconazole, that are applied to agricultural
fields have the same mode of antifungal action as clinical azole drugs. Such long-term application of
azole fungicides to fields could provide selection pressure for the emergence of pan-azole-resistant
strains, such as the A. fumigatus TR34/L98H mutant [11,12]. As a result, there is a continuous need
to improve the efficacy of current antifungal drugs or develop new intervention strategies. Of note,
an invasive A. fumigatus infection (pulmonary) could also be acquired from contaminated foods,
indicating IA further involves public food safety issue [13].
Considering the development of entirely new antifungal drugs is a capital-intensive and
time-consuming process, an alternative approach termed “antifungal drug repurposing” has
been recently investigated. Antifungal drug repurposing is the repositioning process of already
marketed non-antifungal drugs—previously approved for treating other diseases—to control fungal
infections [14]. One of the merits of drug repurposing is that the mechanisms of action, cellular targets
or safety of the commercial drug has already been identified or characterized. However, although
drug repurposing has become a viable approach to accelerate new antifungal drug development,
this strategy still requires highly sensitive screening systems.
Meanwhile, antifungal “chemosensitization” has been developed as a new intervention method,
where co-application of a second compound (viz., chemosensitizer; natural or synthetic), with a
commercial drug has been found to enhance the antifungal efficacy of the co-applied drug [15]. The key
advantage of chemosensitization is that, in contrast to combination therapy (viz., co-application of
two or more commercial antifungal drugs), a chemosensitizer itself does not have to possess a high
level of antifungal potency. Instead, a chemosensitizer causes the target pathogen to become more
susceptible to the commercial co-applied drug by modulating the pathogen’s defense system to the
drug. Chemosensitization could also overcome fungal resistance to certain commercial antifungal
drugs [15].
In this proof of concept study, we tried to develop a high-efficiency drug repurposing method
by targeting the fungal antioxidant system. We applied a previously developed chemosensitization
strategy by including redox-active natural compounds or a structural analog as sensitizers, and also
used fungal mutants lacking key genes in the antioxidant system. This resulted in the enhancement of
the efficacy of the repurposed pro-oxidant drug bithionol. Results indicated that the sensitivity of the
drug repurposing process could be augmented by the chemosensitization method and/or inclusion of
fungal mutants lacking key genes in the cellular targets.
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2. Materials and Methods
2.1. Literature Search: PubMed Database
Articles were retrieved via a PubMed search in the National Center for Biotechnology
Information [16] (https://www.ncbi.nlm.nih.gov/) by using the key words “Drug Antifungal
Repositioning” (Search date: May 31, 2018). The retrieved articles were re-evaluated further for the
relevance of the contents to the subject antifungal drug development: Repositioning of non-antifungal
drugs towards fungal control.
2.2. Chemicals
Chemical compounds, such as aspirin (acetyl salicylic acid), bithionol (2, 2’-sulfanediylbis
(4, 6-dichlorophenol)), octyl gallate (octyl 3,4,5-trihydroxybenzoic acid; OG), thymol (2-isopropyl-5-
methylphenol; THY), 4-isopropyl-3-methylphenol (4I3M), and 3,5-dimethoxybenzaldehyde (3,5-D),
were procured from Sigma Co. (St. Louis, MO, USA). Each compound was dissolved in
dimethylsulfoxide (DMSO; absolute DMSO amount: <2% in media) before incorporation into culture
media. Throughout this study, controls (no treatment) contained DMSO at levels equivalent to that of
cohorts receiving antifungal agents, within the same set of experiments.
2.3. Antifungal Bioassay
Antifungal activities of test compounds were examined in the wild type and two antioxidant
mutants (sakA∆, mpkC∆) of the human pathogen Aspergillus fumigatus AF293 (see below for sources)
and two mycotoxigenic fungi, Aspergillus parasiticus 2999 and A. parasiticus 5862 (National Center for
Agricultural Utilization and Research, USDA-ARS, Peoria, IL, USA). Five µL of each compound was
spotted onto the lawn of test fungi (1 × 104 cfu/mL; potato dextrose agar (PDA) plates), and fungi
were incubated at 35 ◦C for up to 48 hr. The formation of the zone of inhibition was monitored (with
duplicates) at 24 and 48 hr of incubation.
2.4. Overcoming Fludioxonil Tolerance by Bithionol
Determination of overcoming fludioxonil tolerance of A. fumigatus sakA∆ and mpkC∆ mutants
was based on comparison of fungal radial growth between treated and control colonies. Fungal
conidia (5 × 103) were diluted in phosphate buffered saline and inoculated as a drop onto the center of
PDA plates (triplicates) containing: (1) No treatment (control); (2) Bithionol (125 µM); (3) Fludioxonil
(50 µM); and (4) Bithionol + Fludioxonil. Growth was observed for 5 to 7 days at 35 ◦C.
2.5. Statistical Analysis
Statistical analysis (Student’s t-test) was performed based on Reference [17], where p < 0.05 was
considered significant.
3. Results and Discussion
3.1. Aspirin and Bithionol
We initially performed a PubMed database search in the National Center for Biotechnology
Information [16] (https://www.ncbi.nlm.nih.gov/) by using the key words “Drug Antifungal
Repositioning” (Accessed on May 31, 2018), retrieving 70 articles. We re-evaluated the content
of the retrieved articles for their relevance to antifungal drug development, identifying 16 articles
(and references therein), which are shown in Table 1. The remaining 54 articles not selected described:
(1) Antibacterial, antiviral, or antiprotozoal drug development; (2) anticancer drug development; and (3)
drug development for other human diseases such as Parkinson’s disease, hematologic malignancy, etc.
Pharmacological information of the repurposed compounds is also provided in the supplementary
Table S1 [18–38].
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Table 1. Repositioning of non-antifungal drugs to antifungals.
Compounds Functions Repositioning Methods Target Fungi References
Bithionol Anti-parasitic drug High-throughput ATP content
assays
Exserohilum rostratum [39]
Tacrolimus Immunosuppressive agent The same as above E. rostratum [39]
Floxuridine Antimetabolite The same as above E. rostratum [39]
Auranofin Rheumatoid arthritis drug Clinical & Laboratory Standard
Insitute (CLSI) M27-A3 protocol
Candida and Cryptococcus
strains
[40]
Auranofin Rheumatoid arthritis drug CLSI M27-A3 (for yeast) & M38-A2
(for filamentous fungi) protocols
Aspergillus fumigatus,
Scedosporium
apiospermum,
Lomentospora prolificans,
Candida albicans,
Candida krusei,
Cryptococcus neoformans
[41]
Drospirenone Synthetic hormone (birth control
pills) w/ethinylestradiol
Enhancement of amphotericin
B/caspofungin activity against
Candida albicans biofilms (96-well
plate assay)
C. albicans,
Candida glabrata
[42]
Perhexiline Anti-anginal agent The same as above The same as above [42]
Toremifine Selective oestrogen receptor
modulator (Oestrogen
receptor-positive breast cancer
treatment)
The same as above The same as above [42]
Aspirin
(Acetyl salicylic acid)
Anti-pain, fever, or inflammation
drug
European Committee on
Antimicrobial Susceptibility Testing
(EUCAST) protocol
C. neoformans,
Cryptococcus gatti
[43]
Ibuprofen Nonsteroidal anti-inflammatory
drug
The same as above The same as above [43]
Human glycogen synthase
kinase 3 (GSK-3) inhibitors
Neurological disorder drug 24-well plate assay A. fumigatus [44]
Octodrine from Johns
Hopkins Clinical
Compound Library
version 1.0.
Decongestant drug CLSI M44-A2 protocol C. albicans [45]
Amiodarone from
Prestwick library
(Off-patent, biologically
active molecules)
Antiarrhythmic drug High-throughput adenylate kinase
assay
C. neoformans [46]
Thioridazine Antipsychotic drug The same as above C. neoformans [46]
Artesunate from
Pharmakon 1600
repositioning library
Antimalarial drug Miconazole synergy test
(Anti-biofilm testing)
C. albicans [47]
Hexachlorophene Anti-infective (topical) drug The same as above C. albicans [47]
Pyrvinium pamoate Antihelmintic drug The same as above C. albicans [47]
Quinacrine Anti-protozoan drug 96-well plate anti-biofilm testing C. albicans [48]
Cyclo-Phosphamide
(plus 28 drugs)
Anti-cancer drug 96-well anti-filamentation assay C. albicans [49]
Tosedostat from the Enzo
& the Institute for
Molecular Medicine
Finland oncology
collection libraries
Anti-cancer (Aminopeptidase
inhibitor) drug
EUCAST protocol. C. albicans,
C. glabrata
[14]
Chloroquine Anti-malarial drug Microtiter well plate
yeast-to-hyphae transition assay
C. albicans [50]
Aliskiren Anti-hypertensive drug CLSI M27-A2 protocol C. albicans [51]
Atorvastatin Anti-hypercholestero-laemia drug CLSI M27-A3 protocol C. gatti [52]
P21-activated protein
kinase inhibitor
Anti-thyroid cancer drug Agar plate bioassay Fusarium oxysporum,
Fusarium graminearium,
Phytopthora sp.,
Myrothecium roridum,
Helminthosporium maydis.
[53]
We chose “aspirin” and “bithionol” as representative redox-active drugs (for targeting the
fungal antioxidant system) for further investigation (Figure 1a,b). Aspirin (acetyl salicylic acid)
is a non-steroidal anti-inflammatory agent, while bithionol is a halogenated anti-protozoal drug.
Both aspirin and bithionol have been known to participate in reactive oxygen species (ROS)-mediated
apoptosis (programmed cell death) in cancer cells [54,55]. Octyl gallate (OG) was used as a positive
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control, which is a redox-active agent (possessing antioxidant and pro-oxidant activity) interrupting
the lipid bilayer-protein interface in fungal cells (Figure 1c).
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Figure 1. Structures of compounds examined in this study: (a) Aspirin; (b) bithionol; (c) octyl gallate; (d)
thymol (2-isopropyl-5-methylphenol); (e) 4-isopropyl-3-methylphenol; (f) 3,5-dimethoxybenzaldehyde.
3.2. Chemosensitization to Enhance the Efficacy of Repurposed Drugs
Figure 1d,e show examples of chemosensitizers used in this study for targeting fungal
antioxidant systems. Thymol (2-isopropyl-5-methylphenol) is a redox-active natural compound,
and 4-isopropyl-3-methylphenol (4I3M) is a synthetic analog of thymol. We performed zone of
inhibition bioassays, and compared the antifungal efficacy of repurposed drugs for wild type,
antioxidant mutants, wild type with ch m sensitizers, and antioxidant mutan s with chemosensitizers.
Of note, the antioxidant systems of fungi, suc as the mitogen-activ ted protein kinase (MAPK)
signaling athway, have been effect ve antifung l tar ets of redox-active agents. For instance,
A. fumigatus sakA∆ and mpkC∆ are mut nts lacking antioxidant MAPK genes [56,57]. Previous
studies have shown that A. fumigatus akA∆ and mpkC∆ mutants are highly susceptible to redox-active
drugs such as amphotericin B or itraconazole compared to the wild type strain [58,59].
3.2.1. Thymol as a Chemosensitizer to Bithionol or Aspirin
Results showed that antifungal activity of bithionol was greatly enhanced by thymol, while that of
aspirin was almost not affected, indicating “drug-chemosensitizer specificity” exists for the enhancement
of antifungal activity (Figure 2). Drugs were tested at 32 to 1024 µM, with or without 0.6 mM of thymol,
and the positive control OG was tested at 1 and 5 mM. The results also showed that A. fumigatus
MAPK mutants (sakA∆, mpkC∆) were more susceptible to the treatment compared to the wild type,
indicating increased susceptibility of antioxidant mutants to the co-application of redox-active agents,
such as thymol.
Bithionol is an anti-parasitic, “pro-oxidant” drug approved previously by the Food and Drug
Administration [60]. It has recently been shown that co-application of bithionol sensitized ovarian
cancer cells to paclitaxel, thus requiring lower doses of paclitaxel for cancer treatment [54]. Bithionol
synergistically interacted with paclitaxel, where the combined application (bithionol + paclitaxel)
increased the generation of ROS and also enhanced apoptosis in cancer cells [54]. In cancer therapy,
generation of ROS is the key mechanism of apoptosis for chemotherapeutic reagents. Therefore,
increased generation of cellular ROS via combined application of chemotherapeutic drugs with
bithionol contributed to the enhancement of cancer therapy [54]. Co-application of bithionol could
also mitigate the toxic side-effects associated with the high dose treatment of the drug paclitaxel [54].
Methods Protoc. 2019, 2, 31 6 of 14
A similar phenomenon was also observed with the anticancer drug cisplatin, where bithionol augmented
the susceptibility of cisplatin-resistant cell lines to the drug by increasing ROS generation in the cells [61].
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Figure 2. Enhancement of antifungal activity of bithionol by thymol tested in A. fumigatus. THY,
thymol; OG, octyl gallate (positive control).
On the other hand, although aspirin has been shown to participate in ROS-mediated apoptosis
in cancer cells, aspiri played a role as an “antioxidant” until the start of apoptosis in cells, thereby
indicat ng ROS were not the major factors to trigger ap ptosis in aspirin-treated cells [55].
Thymol is redox-active agent, and therefore acts as n antioxidant at low r concentrations.
At hi her conce trations, it functions as a pro-oxidant, inducing oxid ve stress i the C o-2 c ll
line [62]. W speculate that, as observed i ticancer therapy, combin d application of bithionol
and the red x-active thymol could sy ergize to enhance cellular oxidativ stress, which resulted in
i sensitiv ty of ungi (i.e., enhanced zone of inhibit on, Figure 2) to the t eatments, especially
in mutants having defects in a tioxidant systems.
3.2.2. 4-Isopropyl-3-Methylphenol as a Chemosensitizer to Bithionol or Aspirin
The level of bithionol activity was enhanced further when 4I3M, a structural analog of thymol,
was co-applied as a chemosensitizer (Figure 3). For example, the zone of inhibition with 4I3M was
detected at a much lower concentration of bithionol, namely 32 to 128 µM, while that with thymol was
detected at 512 to 1024 µM of bithionol. Also, the sizes of zone of inhibition with 4I3M were larger
than that with thymol. Therefore, results indicated that 4I3M could be more effective chemosensitizer
to bithionol, when compared to thymol in A. fumigatus (Figure 3). As observed in thymol, the activity
of aspirin was alm st not affected by co-treatment with 4I3M.
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Recent studies showed that the yeast Saccharomyces cerevisiae has served as a useful system for
the identification of new antifungal agents and their cellular targets in view that: (1) The S. cerevisiae
genome has been sequenced and well annotated [63], and (2) around 6,000 haploid gene deletion
mutant collections of S. cerevisiae have been the tool for determining drug mode of action [64–66].
Aspergillus species and the model yeast S. cerevisiae also share high homology in the structure of their
antioxidant MAPK signaling systems [67]. This means the genetic or genomic resources of S. cerevisiae,
such as gene deletion mutants of the yeast, could serve as tools for drug screening for control of
Aspergillus species [64–66].
Yeast dilution bioassay in a prior study showed the “sensitive” responses of yeast vacuolar and
antioxidant gene deletion mutants to 4I3M, indicating 4I3M negatively affects both cellular ion and
“redox” homeostasis in fungi [68]. We previously observed similar results with thymol [58], further
indicating 4I3M and thymol share analogous cellular targets in fungi. 4I3M is a synthetic analog of
thymol, a natural product. As with thymol, 4I3M has been used as an antimicrobial preservative in
personal care products, where 4I3M is more appealing to consumer perception compared to thymol
due to its color/odor-neutral characteristic [68].
We applied the same strategy in Aspergillus parasiticus, a mycotoxigenic fungus producing
hepato-carcinogenic aflatoxins. Chemosensitization effects of thymol or 4I3M to bithionol were
also observed in A. parasiticus (Figure 4). However, unlike in A. fumigatus, thymol exhibited higher
sensitizing activity compared to its analog 4I3M in A. parasiticus (Figure 4). Also, the sizes of zone
of inhibition in A. parasiticus were generally smaller than that observed in A. fumigatus, indicating
“strain-specificity” also exists for the efficacy of chemosensitization when bithionol is co-applied with
thymol or 4I3M.
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Figure 4. Enhancement of antifungal activity of bithionol by thymol or 4I3M tested in the aflatoxigenic
A. pa asiticus 2999. THY, thymol; 4I3M, 4-isopropyl-3-methylp enol; OG, octyl gallate (positive control).
A. fumigatus is a human/animal pathogen, while A. parasiticus mostly contaminates crops or
foods. We recently observed that A. fumigatus was able to survive at high temperature (55 ◦C),
while A. parasiticus could not grow t the sa e t mperature [69]. Alth ugh such differences in niches
and/or environmental responsiveness might contribute to the “strain-specificity” determined in this
study, elucidation of precise mechanisms exerting strain-specificity warrants future investigation.
3.2.3. 3,5-Dimethoxybenzaldehyde as a Chemosensitizer to Bithionol or Aspirin
We investigated the effect of other types of chemosensitizer for the enhancement of bithionol
activity. The 3,5-dimethoxybenzaldehyde (3,5-D) (Figure 1f) also targets antioxidant systems in fungi,
as determined in the model yeast S. cerevisiae (Supplementary Table S2 [59,70]). 3,5-D negatively
affected the cellular antioxidant system, such as superoxide dismutase or glutathione reductase [59].
As determined in thymol or 4I3M co-treatment, antifungal activity of bithionol was also enhanced
when the drug was co-applied with 3,5-D (Figure 5). Similar to thymol or 4I3M co-treatment, antifungal
activity of aspirin was almost unaffected when 3,5-D was co-applied as a chemosensitizer (Figure 5).
Methods Protoc. 2019, 2, 31 8 of 14
In general, the level of the enhancement of bithionol activity with 3,5-D was lower than that observed
with thymol or 4I3M, which was reflected in smaller sizes of zone of inhibition.
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Figure 5. Enhancement of antifungal activity of bithionol by 3,5-dimethoxybenzaldehyde tested in
A. fumigatus. 3,5-D, 3,5-dimethoxybenzaldehyde; OG, octyl gallate (positive control).
Similar results were obtained in the aflatoxin-producing A. parasiticus, where the sizes of
zone of inhibition were generally smaller than that observed in A. fumigatus. Therefore, results
indicated that “strain-specificity” also existed for the enhancement of the efficacy of “bithionol and
3,5-dimethoxybenzaldehyde” co-treatment in different Aspergillus species (Figure 6).
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Figure 6. Enhancement of the antifungal activity of bithionol by 3,5-dimethoxybenzaldehyde
tested in the aflatoxigenic A. parasiticus 5862. 3,5-D, 3,5-dimethoxybenzaldehyde; OG, octyl gallate
(positive control).
We also speculate that quantitation of the precise level of interactions between compounds—such
as synergistic, additive, neutral or antagonistic interactions—during chemosensitization can be
determined in future investigations by the methods outlined by the Clinical Laboratory Standards
Institute (CLSI) M38-A [71] or the European Committee on Antimicrobial Susceptibility Testing
(EUCAST) [72]; definitive document EDef 7.2.].
3.3. Scheme of High-Efficiency Drug Repurposing Design
Figure 7 describes the scheme of high-efficiency drug repurposing design based on the current
investigation, which targets the fungal antioxidant system. When the wild type strain is used during
the drug repurposing process, it is considered a “low sensitivity” screening, and thus we expect to
obt in a small number of repurposed drugs. When mutants, such as anti xidant mutants, are used
or the wil type is used with redox-active sen iti ing agents, it is considered a “medium sensitivity”
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screening, and thus we expect to obtain a medium number of repurposed drugs. When antioxidant
mutants are used with redox-active chemosensitizers, it is considered a “high sensitivity” screening,
so that we expect the isolation of a large number of repurposed drugs.
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Regarding the chemosensitizers, we speculated that (as determined in this study with thymol/4I3M and
bithionol) application of chemosensitizers with similar modes of action or cellular targets as the candidate
drugs (e.g., pro-oxidant + pro-oxidant, cell wall/membrane disruptors + cell wall/membrane disruptors, etc.)
would result in higher sensitivity of the drug repurposing process. Examples of antifungal chemosensitizers
identified include: (a) 4-methoxy-2,3,6-trimethylbenzensulfonyl- substituted d-octapeptide sensitizing
Candida strains to fluconazole [73]; (b) 7-chlorotetrazolo [5,1-c]benzo [1,2,4]triazine sensitizing Candida
and Saccharomyces strains to azole drugs [74]; and (c) benzhydroxamic acid sensitizing Rhizopus oryzae
to triazoles, such as posaconazole and itraconazole [75] (see also Supplementary Table S2 [59,69,70,76]).
Identification of comprehensive numbers of chemosensitizers affecting different cellular targets also
requires future in-depth study.
3.4. Overcoming Fludioxonil Tolerance of Aspergillus Fumigatus MAPK Mutants
Fludioxonil (phenylpyrrole) is a commercial antifungal agent, which induces abnormal and
excessive stimulation of the oxidative stress MAPK signaling system [77]. However, fungi having
mutations in oxidative stress MAPK pathway can escape the fludioxonil toxicity [77]. As shown in
Figure 8, two MAPK mutants (sakA∆, mpkC∆) of A. fumigatus exhibited tolerance to fludioxonil at
50 µM, and developed radial growth on PDA, while the growth of the wild type was completely
disrupted. However, co-application of sub-fungicidal concentration of bithionol with fludioxonil
effectively prevented fungal tolerance to fludioxonil, therefore achieving complete inhibition of the
growth of two MAPK mutants. The Student’s t-test for paired data (combined, i.e., bithionol +
fludioxonil) was versus bithionol alone or fludioxonil alone and determined in sakA∆ and mpkC∆
strains, where the p values for “combined” were determined as <0.005 for both versus bithionol only
and fludioxonil only.
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Figure 8. Bithionol overcomes fludioxonil resistance of Aspergillus fumigatus MAPK mutants.
In fungi, environmental signals, such as oxidative stress signals, are integrated into the MAPK
signaling system, regulating the expression of downstream genes that are countering the stress [78,79].
Therefore, we speculate that, by co-applying a pro-oxidant agent (such as bithionol) with fludioxonil,
these tolerant MAPK mutants became more susceptible to the treatment, since the mutated MAPK
system of fungi was incapable of initiating a fully operational oxidative stress response including the
production of antioxidant enzymes.
4. Conclusions
In summary, a high sensitivity antifunga screening method was investigated by incorporating
redox-active che osensitizers and antioxid nt mutants of A. fumigatu . Redox-active compounds,
such as thymol, 4I3M or 3,5-D, can be used as poten chemo e sitizers to enhance antimycotic activity
of the repurp d drug bithionol, while the efficacy of the other drug aspiri wa almost not affected,
indicating “chemosensitizer–drug specificity” exists. The difference in antifungal efficacy betwe n
bithionol and aspirin could b based on t eir role as either “pro-oxidant (bithionol)” or “antioxidan
(asp rin)” dur ng treatm nts (se above). While imilar enhancement of antifungal efficacy was
also observed in the mycotoxin-producing A. parasiticus, the level of sensitivity of this species to
the treatments was not comparable to that of A. fumigatus, thus indicating “strain-specificity” also
exists during chemosensitization. Application of compounds with similar mechanisms of action
(e.g., pro-oxidant, cell wall/membrane disruptors, etc.) or cellular targets (e.g., antioxidant system,
cell wall/membrane integrity system, etc.) to that of the candidate drugs is suggested, which would
result in higher sensitivity of the drug repurposing process.
Current results could be used for the development of high-efficiency, large-scale repositioning of
marketed drugs, which can reduce costs, abate resistance, and alleviate negative side effects associated
with current antifungal treatments. Inclusion of additional databases, such as DrugCentral [80] and
Aggregate Analysis of ClinicalTrials.gov (AACT) [81], etc., might enhance the comprehensiveness of
antifungal drug repositioning in the future study.
Supplementary Materials: The following are available online at http://www.mdpi.com/2409-9279/2/2/31/s1,
Table S1: Pharmacology of repositioned compounds, Table S2: Examples of chemosensitizers targeting antioxidant
or cell wall systems in fungi previously determined in the model yeast Saccharomyces cerevisiae.
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